Clinical Trial Update: Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial listing describes a Phase 2 neoadjuvant study of donafenib combined with sintilimab and hepatic arterial infusion chemotherapy for resectabl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING